ImmunoPrecise Antibodies lines up acquisition of Dutch biotech

Crossbeta has developed an innovative technology to generate stable oligomers for drug discovery and development in disease areas characterized by the presence of misfolded proteins, such as Alzheimer’s, Parkinson’s and Huntington’s disease
Alzheimer's disease affects neural pathways
Crossbeta's technology has already yielded multiple antibodies with biomarker/diagnostic and therapeutic potential for Alzheimer's and Parkinson's disease

ImmunoPrecise Antibodies Ltd (CVE:IPA) is lined up to acquire Crossbeta Biosciences, a Dutch company with a proprietary technology for efficient oligomer-based drug discovery.

The €8.5mln (C$12.84mln) acquisition, should it go ahead, would allow ImmunoPreceise Anitbodies (IPA) to build a pipeline of antibodies with applications in biomarker/diagnostic assays and antibody solutions therapeutics.

IPA will either pay for the acquisition through the issue of shares or the use of convertible notes carrying a coupon of 6%.

The Canadian company has also indicated it would pump €15mln (C$22.65mln) into the company, with some of that planned investment triggered by milestone achievements.

IPA said the purchase of the privately-held company would significantly further its ambition of becoming a single-source provider of services across the full antibody discovery value chain (antigen design, hit generation, lead selection, lead optimization and lead characterization) and of offering the full spectrum of antibody production methodologies (library-based technologies, hybridoma methods, transgenic animal based platforms and single B cell-based technology).

Furthermore, the acquisition enhances the company's source of, and capacity for, developing unique antigens for generating and selecting antibodies.

"In acquiring Crossbeta Biosciences BV, IPA becomes a leading integrated antibody solutions company with high-value potential biomarker/diagnostic and therapeutic assets," said James Kuo, the chairman and interim president of the company.

View full IPA profile View Profile

Immunoprecise Antibodies Ltd Timeline

Related Articles

August 22 2018
So far, the hit rate is a five out of 12 success rate for its investments
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.